• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International clinical psychopharmacology >Switching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics: analysis of a Medicaid claims database
【24h】

Switching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics: analysis of a Medicaid claims database

机译：从利培酮长效注射剂改为帕潘立酮长效注射剂或口服抗精神病药：医疗补助索赔数据库的分析

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

This report examines relapse risk following a switch from risperidone long-acting injectable (RLAI) to another long-acting injectable antipsychotic [paliperidone palmitate (PP)] versus a switch to oral antipsychotics (APs). Truven Health's MarketScan Multistate Medicaid Database compared relapses following switches from RLAI. New user cohorts for these two groups were created on the basis of first incidence of exposure to the 'switched to' drug. Groups were balanced using 1: 1 propensity score matching. Time-to-event analysis assessed schizophrenia-related hospital/emergency department visits. A total of 188 patients switched from RLAI to PP, and 131 patients switched from RLAI to oral AP. Propensity score-matched cohort included 109 patients who switched to PP and 109 patients who switched to an oral AP. Patients who switched from RLAI to PP had fewer events (26 vs. 32), longer time to an event (mean 70 vs. 47 days), and lower risk of relapse (hazard ratio, 0.54; 95% confidence interval, 0.32-0.92; P=0.024) compared with those who switched from RLAI to oral AP. Switching from RLAI to PP may be associated with a lower risk for relapse and longer duration of therapy compared with switching to oral AP. Given the limitations of observational studies, these results should be confirmed by other prospective evaluations. Copyright (C) 2015 Wolters Kluwer Health, Inc. All rights reserved.
机译：本报告探讨了从利培酮长效注射剂（RLAI）切换至另一种长效抗精神病药[paliperidone palmitate（PP）]与口服抗精神病药（APs）切换后的复发风险。 Truven Health的MarketScan多州医疗补助数据库比较了从RLAI切换后的复发情况。根据“转用”药物的首次接触发生率，为这两个群体创建了新的使用者队列。使用1：1的倾向得分匹配来平衡各组。事件发生时间分析评估了与精神分裂症相关的医院/急诊科的就诊情况。共有188例患者从RLAI切换为PP，131例患者从RLAI切换为口服AP。倾向得分匹配的队列包括109例改用PP的患者和109例改用口服AP的患者。从RLAI切换为PP的患者发生事件的次数更少（26 vs. 32），发生事件的时间更长（平均70 vs. 47天），复发风险更低（危险比，0.54; 95％置信区间，0.32-0.92 ; P = 0.024）与那些从RLAI改为口服AP的患者相比。与改用口服AP相比，从RLAI切换为PP可能与复发风险较低，治疗时间更长有关。鉴于观察性研究的局限性，这些结果应通过其他前瞻性评估予以证实。版权所有（C）2015 Wolters Kluwer Health，Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号